[go: up one dir, main page]

AR105812A1 - Métodos para la preparación de inhibidores de proteína deacetilasa - Google Patents

Métodos para la preparación de inhibidores de proteína deacetilasa

Info

Publication number
AR105812A1
AR105812A1 ARP160101701A ARP160101701A AR105812A1 AR 105812 A1 AR105812 A1 AR 105812A1 AR P160101701 A ARP160101701 A AR P160101701A AR P160101701 A ARP160101701 A AR P160101701A AR 105812 A1 AR105812 A1 AR 105812A1
Authority
AR
Argentina
Prior art keywords
compound
formula
preparation
deacetilase
inhibitors
Prior art date
Application number
ARP160101701A
Other languages
English (en)
Inventor
H Van Duzer John
Seyedi Farzaneh
Original Assignee
Acetylon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acetylon Pharmaceuticals Inc filed Critical Acetylon Pharmaceuticals Inc
Publication of AR105812A1 publication Critical patent/AR105812A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30Halogen atoms or nitro radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Reivindicación 1: Un método para la preparación del compuesto de fórmula (1), que comprende los pasos de: la conversión del compuesto de fórmula (2) en el compuesto de fórmula (3); en el que X se selecciona de flúor, cloro, bromo y yodo; Z se selecciona del grupo que consiste en -CN y -CO₂R; y R es alquilo C₁₋₆; y la conversión del compuesto de fórmula (3) en el compuesto de fórmula (1). Reivindicación 20: Una composición que comprende un compuesto de fórmula (4); en la que Z se selecciona del grupo que consiste en CN y -CO₂R; y en la que R es alquilo C₁₋₆; y un compuesto de fórmula (5), en la que Z se selecciona del grupo que consiste en -CN y CO₂R; y en la que R es alquilo C₁₋₆. Reivindicación 24: Un compuesto que tiene la estructura de fórmula (6) en el que Z se selecciona del grupo que consiste en -CN y -CO₂R; y en el que R es alquilo C₁₋₆. Reivindicación 27: Una composición que comprende el compuesto de acuerdo con la reivindicación 24.
ARP160101701A 2015-06-08 2016-06-08 Métodos para la preparación de inhibidores de proteína deacetilasa AR105812A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562172624P 2015-06-08 2015-06-08

Publications (1)

Publication Number Publication Date
AR105812A1 true AR105812A1 (es) 2017-11-15

Family

ID=56264043

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160101701A AR105812A1 (es) 2015-06-08 2016-06-08 Métodos para la preparación de inhibidores de proteína deacetilasa

Country Status (11)

Country Link
US (1) US10144714B2 (es)
EP (1) EP3303304B1 (es)
JP (1) JP6873053B2 (es)
CN (1) CN107922352B (es)
AR (1) AR105812A1 (es)
AU (2) AU2016276573A1 (es)
CA (1) CA2988594C (es)
ES (1) ES2769255T3 (es)
MX (1) MX369349B (es)
TW (1) TWI706937B (es)
WO (1) WO2016200930A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105753739A (zh) 2010-01-22 2016-07-13 埃斯泰隆制药公司 作为蛋白质去乙酰化酶抑制剂的反向酰胺化合物及其使用方法
US9663825B2 (en) 2012-04-19 2017-05-30 Acetylon Pharmaceuticals, Inc. Biomarkers to identify patients that will respond to treatment and treating such patients
AR104935A1 (es) 2015-06-08 2017-08-23 Acetylon Pharmaceuticals Inc Formas cristalinas de un inhibidor de histona deacetilasa
WO2016200930A1 (en) 2015-06-08 2016-12-15 Acetylon Pharmaceuticals, Inc. Methods of making protein deacetylase inhibitors
WO2017214565A1 (en) * 2016-06-09 2017-12-14 Dana-Farber Cancer Institute, Inc., Methods of use and pharmaceutical combinations of hdac inhibitors with bet inhibitors
EP3496751B1 (en) 2016-08-08 2022-10-19 Acetylon Pharmaceuticals Inc. Pharmaceutical combinations of histone deacetylase 6 inhibitors and cd20 inhibitory antibodies and uses thereof
WO2018098168A1 (en) 2016-11-23 2018-05-31 Acetylon Pharmaceuticals, Inc. Pharmaceutical combinations comprising a histone deacetylase inhibitor and a programmed death-ligand 1 (pd-l1) inhibitor and methods of use thereof

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
WO2001070675A2 (en) 2000-03-24 2001-09-27 Methylgene, Inc. Inhibitors of histone deacetylase
US20050119305A1 (en) 2001-03-21 2005-06-02 Masao Naka Il-6 production inhibitors
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
MXPA04004177A (es) 2001-11-01 2004-09-06 Janssen Pharmaceutica Nv Derivados de amida como inhibidores de la glicogeno cintasa cinasa 3-beta.
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP2006520796A (ja) 2003-03-17 2006-09-14 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼインヒビター
WO2005007091A2 (en) 2003-07-07 2005-01-27 Georgetown University Histone deacetylase inhibitors and methods of use thereof
CN101010298A (zh) 2004-04-05 2007-08-01 默克Hdac研究有限责任公司 组蛋白脱乙酰酶抑制剂前药
CA2601706C (en) 2005-03-22 2016-09-20 Dana-Farber Cancer Institute, Inc. Treatment of protein degradation disorders
WO2007022638A1 (en) 2005-08-26 2007-03-01 Methylgene Inc. Benzodiazepine and benzopiperazine analog inhibitors of histone deacetylase
CN101400362B (zh) 2006-02-14 2016-10-12 哈佛大学校长及研究员协会 双官能组蛋白去乙酰化酶抑制剂
AU2007248656B2 (en) 2006-05-03 2013-04-04 Dana-Farber Cancer Institute, Inc. Histone deacetylase and tubulin deacetylase inhibitors
WO2007144341A1 (en) 2006-06-12 2007-12-21 Vrije Universiteit Brussel Differentiation of rat liver epithelial cells into hepatocyte-like cells
ES2288802B1 (es) 2006-07-07 2008-12-16 Universidad De Granada Nuevos derivados de ftalimida como inhibidores de las histonas desacetilasas.
US7888361B2 (en) 2006-09-11 2011-02-15 Curis, Inc. Tyrosine kinase inhibitors containing a zinc binding moiety
CN101951930A (zh) 2008-02-19 2011-01-19 阿奈斯特药品株式会社 对身体功能的恢复有用的口服或经肠组合物
WO2010011296A2 (en) 2008-07-23 2010-01-28 President And Fellows Of Harvard College Deacetylase inhibitors and uses thereof
US8716326B2 (en) 2009-05-15 2014-05-06 Korea Research Institute Of Chemical Technology Isoindolinone derivatives, preparation method thereof and a pharmaceutical composition comprising same
WO2011019393A2 (en) 2009-08-11 2011-02-17 President And Fellows Of Harvard College Class- and isoform-specific hdac inhibitors and uses thereof
ES2609040T3 (es) * 2009-12-17 2017-04-18 Merck Sharp & Dohme Corp. Aminopirimidinas como inhibidores de Syk
WO2011084991A2 (en) 2010-01-08 2011-07-14 President And Fellows Of Harvard College Fluorinated hdac inhibitors and uses thereof
CN105753739A (zh) 2010-01-22 2016-07-13 埃斯泰隆制药公司 作为蛋白质去乙酰化酶抑制剂的反向酰胺化合物及其使用方法
WO2011146855A1 (en) 2010-05-21 2011-11-24 The Trustees Of Columbia University In The City Of New York Selective hdac inhibitors
WO2012018499A2 (en) 2010-08-05 2012-02-09 Acetylon Pharmaceuticals Specific regulation of cytokine levels by hdac6 inhibitors
CN107011270A (zh) 2010-11-16 2017-08-04 阿塞蒂隆制药公司 作为蛋白质去乙酰化酶抑制剂的嘧啶羟基酰胺化合物和其使用方法
JP6169076B2 (ja) 2011-07-20 2017-07-26 ザ ジェネラル ホスピタル コーポレイション 骨疾患の処置のためのヒストン脱アセチル化酵素6選択的阻害剤
US8841301B2 (en) 2011-09-26 2014-09-23 Bristol-Myers Squibb Company Selective NR2B antagonists
JP5724851B2 (ja) * 2011-11-30 2015-05-27 東レ株式会社 N−(ヨードフェニル)ピリミジニルアミン誘導体の製造方法
US9663825B2 (en) 2012-04-19 2017-05-30 Acetylon Pharmaceuticals, Inc. Biomarkers to identify patients that will respond to treatment and treating such patients
JP2015533173A (ja) 2012-10-12 2015-11-19 トラスティース・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア タンパク質脱アセチル化酵素阻害剤としてのピリミジンヒドロキシアミド化合物およびその使用方法
US9145412B2 (en) 2012-11-02 2015-09-29 Acetylon Pharmaceuticals, Inc. Selective HDAC1 and HDAC2 inhibitors
US9139583B2 (en) 2013-02-01 2015-09-22 Acetylon Pharmaceuticals, Inc. Selective HDAC3 inhibitors
JP2016511237A (ja) 2013-02-01 2016-04-14 アセチロン ファーマシューティカルズ インコーポレイテッドAcetylon Pharmaceuticals,Inc. 選択的hdac3阻害剤
EP3004141A4 (en) 2013-06-03 2017-05-31 Acetylon Pharmaceuticals, Inc. Histone deacetylase ( hdac) biomarkers in multiple myeloma
JP2016531163A (ja) 2013-09-20 2016-10-06 アセチロン ファーマシューティカルズ インコーポレイテッドAcetylon Pharmaceuticals,Inc. Hdac6阻害物質を用いた、異常なリンパ球の機能に起因する疾患の治療
US9403779B2 (en) 2013-10-08 2016-08-02 Acetylon Pharmaceuticals, Inc. Combinations of histone deacetylase inhibitors and either Her2 inhibitors or PI3K inhibitors
JP2016536354A (ja) 2013-10-10 2016-11-24 アセチロン ファーマシューティカルズ インコーポレイテッドAcetylon Pharmaceuticals,Inc. 非ホジキンリンパ腫を治療するための、hdac阻害剤単独またはbtk阻害剤との組み合わせ
EP3054953B1 (en) 2013-10-10 2020-07-01 Acetylon Pharmaceuticals, Inc. Hdac inhibitors in combination with pi3k inhibitors, for treating non-hodgkin's lymphoma
US9278963B2 (en) 2013-10-10 2016-03-08 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors
AU2014332147A1 (en) 2013-10-11 2016-05-05 Acetylon Pharmaceuticals, Inc. Combinations of histone deactylase inhibitors and immunomodulatory drugs
US10660890B2 (en) 2013-10-24 2020-05-26 National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs), U.S. Government Nih Division Of Extramural Inventions And Technology Resources (Deitr) Treatment of polycystic diseases with an HDAC6 inhibitor
BR112016012561A2 (pt) 2013-12-03 2017-08-08 Acetylon Pharmaceuticals Inc Combinações de inibidores da histona desacetilase e fármacos imunomoduladores
EP3084446B1 (en) 2013-12-20 2022-12-14 Acetylon Pharmaceuticals, Inc. Histone deacetylase 6 (hdac6) biomarkers in multiple myeloma
US9464073B2 (en) 2014-02-26 2016-10-11 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors
US20150359794A1 (en) 2014-06-13 2015-12-17 Buck Institute For Research On Aging Impairment of the large ribosomal subunit protein rpl24 by depletion or acetylation
JP6952602B2 (ja) 2014-07-07 2021-10-20 アセチロン ファーマシューティカルズ インコーポレイテッドAcetylon Pharmaceuticals,Inc. ヒストンデアセチラーゼ阻害剤による白血病の治療
WO2016057779A2 (en) 2014-10-08 2016-04-14 Acetylon Pharmaceuticals, Inc. Induction of gata2 by hdac1 and hdac2 inhibitors
WO2016090230A1 (en) 2014-12-05 2016-06-09 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds for treating peripheral neuropathy
WO2016087950A1 (en) 2014-12-05 2016-06-09 University of Modena and Reggio Emilia Combinations of histone deacetylase inhibitors and bendamustine for use in the treatment of lymphoma
SG11201704759QA (en) 2014-12-12 2017-07-28 Regenacy Pharmaceuticals Llc Piperidine derivatives as hdac1/2 inhibitors
WO2016168647A1 (en) 2015-04-17 2016-10-20 Acetylon Pharmaceuticals Inc. Treatment of neuroblastoma with histone deacetylase inhibotrs
US10272084B2 (en) 2015-06-01 2019-04-30 Regenacy Pharmaceuticals, Llc Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy
AR104935A1 (es) 2015-06-08 2017-08-23 Acetylon Pharmaceuticals Inc Formas cristalinas de un inhibidor de histona deacetilasa
WO2016200930A1 (en) 2015-06-08 2016-12-15 Acetylon Pharmaceuticals, Inc. Methods of making protein deacetylase inhibitors
EP3496751B1 (en) 2016-08-08 2022-10-19 Acetylon Pharmaceuticals Inc. Pharmaceutical combinations of histone deacetylase 6 inhibitors and cd20 inhibitory antibodies and uses thereof

Also Published As

Publication number Publication date
AU2016276573A1 (en) 2018-01-04
TWI706937B (zh) 2020-10-11
ES2769255T3 (es) 2020-06-25
MX2017015900A (es) 2018-11-09
WO2016200930A9 (en) 2017-02-23
CN107922352B (zh) 2021-08-06
US20160355486A1 (en) 2016-12-08
CA2988594C (en) 2023-08-15
JP2018518486A (ja) 2018-07-12
EP3303304B1 (en) 2019-11-20
TW201718517A (zh) 2017-06-01
US10144714B2 (en) 2018-12-04
AU2020267299B2 (en) 2022-07-07
AU2020267299A1 (en) 2020-12-10
EP3303304A1 (en) 2018-04-11
WO2016200930A1 (en) 2016-12-15
MX369349B (es) 2019-11-06
CN107922352A (zh) 2018-04-17
CA2988594A1 (en) 2016-12-15
JP6873053B2 (ja) 2021-05-19

Similar Documents

Publication Publication Date Title
AR105812A1 (es) Métodos para la preparación de inhibidores de proteína deacetilasa
CL2020002269A1 (es) Anticuerpo que se une a redil33; polinucleótido; vector; célula hospedadora; método para producir el anticuerpo; composición farmacéutica; producto de combinación; uso del anticuerpo para tratar una afección inflamatoria (divisional de la solicitud no. 201702433)
ECSP18094790A (es) Piridinas sustituidas con heteroarilo y métodos de uso referencia cruzada a solicitudes relacionadas
EA201890522A1 (ru) Способ получения противогрибковых соединений
MX2020010841A (es) Composicion detergente.
EA201691649A1 (ru) Способ получения противогрибковых соединений
MX2018006148A (es) Inhibidores de cxcr2.
MX373717B (es) Composiciones concentradas para la limpieza personal y metodos.
EA201692219A1 (ru) Способы получения противовирусных соединений
CO2017002253A2 (es) Compuesto dirigido a il-23a y tnf-alfa
CL2016003301A1 (es) Compuestos derivados del ácido amino-(piridin-4-carboxílico) sustituidos, inhibidores de la histona desmetilasa; composición farmacéutica, que los comprende, útiles en el tratamiento del cáncer, tales como el cáncer de próstata, mama, vejiga, pulmón y/o melanoma.
EA201490458A1 (ru) Способ получения тернесита
DOP2017000278A (es) Piridinas sustituidas y método de uso
MX392317B (es) Proceso para la preparación de etilenglicol a partir de azúcares.
EA201691648A1 (ru) Способ получения противогрибковых соединений
DOP2014000048A (es) Composiciones farmacéuticas que comprenden un polisacárido y un inhibidor hdac
AR100232A1 (es) Detergente
EP3504185A4 (en) NEW SUBSTITUTED N'-HYDROXYCARBAMIMIDOYL-1,2,5-OXADIAZOLE COMPOUNDS AS INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE (IDO)
BR112019025028A2 (pt) Método para preparar um composto.
CO2018010694A2 (es) Una composición de componente único o múltiple para la producción de un hidrogel
EA201500931A1 (ru) Производные пиридин-4-ила
CL2017000484A1 (es) Compuestos de azetidiniloxifenilpirrolidina
MX387796B (es) Compuestos de aminocarbonilcarbamato.
CL2017001615A1 (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2.
DOP2017000189A (es) Compuestos de benzoxaborol y usos de los mismos